Intensity Therapeutics

Intensity Therapeutics is a clinical stage, biotechnology company whose mission is to create safer and more efficacious cancer therapies.

Nasdaq: $INTS

[Intensity Therapeutics @IntensityInc]

$INTS reported Q1 2026 financial results & a corporate update, including favorable preliminary observations from the Phase 2 INVINCIBLE-4 study in #TNBC.

#INTS also plans to resume enrollment in the Phase 3 INVINCIBLE-3 sarcoma study by Q3 2026.

Full PR: https://t.co/5DOt4FNBRv

[Intensity Therapeutics @IntensityInc]

Highlighting $INTS' senior management team.

With deep experience across #biotech and drug development, the team continues advancing Intensity's mission in cancer treatment innovation.

Learn more: https://t.co/H4a2wFgPXk

[Intensity Therapeutics @IntensityInc]

#ICYMI: Lewis Bender, CEO of $INTS, recently shared insights with Biopharma Boardroom on the potential of INT230-6 and the evolving future of intratumoral therapies.

Catch up here: https://t.co/2vmhHWvdnr

[Intensity Therapeutics @IntensityInc]

$INTS' Founder & CEO, Lewis Bender, reflected on the Company’s recent recognition as the 2026 Cancer Treatment Technology Innovator Award winner.

See the @Global_H_Pharma award winners: https://t.co/DctY7Mvc9u

#GHPAward

[Intensity Therapeutics @IntensityInc]

May is #NationalCancerResearchMonth, underscoring the role of  #cancerresearch in advancing new treatments.

$INTS is advancing a novel intratumoral approach to treat cancer at any stage, activating a systemic immune response.

#NCRMonth #Oncology

[Intensity Therapeutics @IntensityInc]

This fall, $INTS will participate in the Novel Modalities stream at @BostonDOT.

On Oct. 1 at 4:05 PM, #INTS Founder & CEO Lewis Bender will present on advances in intratumoral drug delivery and tumor uptake of anticancer agents.

Learn more: https://t.co/fQ8EOTBXPh

#BostonDOT

[Intensity Therapeutics @IntensityInc]

$INTS is proud to share we’ve received the @Global_H_Pharma 2026 Cancer Treatment Technology Innovator Award!

#INTS is advancing an intratumoral approach to treat tumors locally and activate a systemic immune response.

Honored to be included.

Read more: https://t.co/y5tyTIXzy8

#GHPAward

[Intensity Therapeutics @IntensityInc]

National Women’s Health Week highlights the need for progress in #breastcancer.

$INTS is advancing an intratumoral approach in #TNBC to treat tumors locally & activate a systemic immune response.

Innovation in #womenhealth remains critical to improving patient outcomes.

#NWHW

[Intensity Therapeutics @IntensityInc]

Last night, $INTS attended @Runway4Recovery's Runway Show NYC in support of #breastcancerawareness.

#INTS' CEO Lew Bender, joined Eve Bender, VP of sales at @FValentineNY, who dressed five models for the event.

An inspiring evening honoring those impacted.

#RunwayForRecovery

[Intensity Therapeutics @IntensityInc]

About 350,000 women are diagnosed with breast cancer annually.

The Runway Show last night was a powerful celebration of 85 women who beat or are fighting #breastcancer, including my sister.

Intensity remains committed to developing a new drug that someday will help more BC patients live healthier, longer lives. - ‌Lewis Bender

[Intensity Therapeutics @IntensityInc]

About 350,000 women are diagnosed with breast cancer annually.

The Runway Show last night was a powerful celebration of 85 women who beat or are fighting #breastcancer, including my sister.

Intensity remains committed to developing a new drug that someday will help more BC patients live healthier, longer lives. - ‌Lewis Bender

[Intensity Therapeutics @IntensityInc]

Last night, $INTS attended @Runway4Recovery's Runway Show NYC in support of #breastcancerawareness.

#INTS' CEO Lew Bender, joined Eve Bender, VP of sales at @FValentineNY, who dressed five models for the event.

An inspiring evening honoring those impacted.

#RunwayForRecovery

[Intensity Therapeutics @IntensityInc]

Tonight, $INTS is attending the 2nd Annual Runway Show NYC with @Runway4Recovery.

85 survivors will take the runway, with @katiecouric as Spotlight Model.

Proud to support.

#RunwayForRecovery

[Intensity Therapeutics @IntensityInc]

$INTS' VP Clinical Ops, Kimberly A. Guedes, will join @PrecisionEvolu1's Clinical Trials Summit in Boston starting today for a fireside chat on addressing trial risk earlier in development.

#PCSummit #LeadershipInsights

[Intensity Therapeutics @IntensityInc]

New approaches are needed to treat #cancer at every stage.

$INTS is developing an #intratumoral platform designed to target tumors directly while supporting a broader immune response.

Learn more: https://t.co/JKpu0GlELK

[Intensity Therapeutics @IntensityInc]

For decades, #solidtumors have been difficult to treat due to their dense structure and protective microenvironment.

CEO Lew Bender discusses how $INTS is developing intratumoral therapies to target tumors directly and overcome these barriers.

Read more: https://t.co/6JO1W2KFit

[Intensity Therapeutics @IntensityInc]

$INTS recently shared a Phase 2 INVINCIBLE-4 update for INT230-6 in #TNBC.

Preliminary observations showed higher pCR and fewer high-grade AEs vs SOC. Enrollment restart pending.

Read more: https://t.co/pFGqcz2J7X

#ClinicalTrials

[Intensity Therapeutics @IntensityInc]

$INTS has received a Platinum Pinnacle Healthcare Award for Innovator in Biotech Solutions!

This recognition reflects our focus on advancing novel approaches, including our #intratumoral platform and lead candidate #INT2306.

Read more: https://t.co/tJ8QenQ5JG

#PinnacleAwards

[Intensity Therapeutics @IntensityInc]

In a new Biopharma Boardroom interview, $INTS' CEO, Lewis Bender, discusses INT230-6 and its approach to combining tumor cell killing with immune activation.

Read the full interview: https://t.co/2vmhHWuFxT

#Oncology #ClinicalTrials

[Intensity Therapeutics @IntensityInc]

In a new @_CellandGene article, $INTS Founder and CEO ‌Lewis Bender explores how intratumoral therapy could reshape the treatment of solid tumors.

Read the full article: https://t.co/Zwgv1bD5qy

#INT2306